APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Influenza Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174014860330 December 2025194 pages

Choose your research edition.

Industry ResearchMultivalent Influenza Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Multivalent Influenza Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multivalent Influenza Vaccines include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multivalent Influenza Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multivalent Influenza Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multivalent Influenza Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multivalent Influenza Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Multivalent Influenza Vaccines Segment by Company

CSL

KM Biologics

Viatris

AstraZeneca

Bcht Biotechnology

Sinovac

Aleph Biomedical

GSK

ADIMMUNE Corporation

Hualan Bio

Jiangsu GDK

Sanofi

Shanghai Institute of Biological Products

Wuhan Institute of Biological Products

Changchun Institute of Biological

Zhongyianke Biotech

Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years

Above 3 Years

Multivalent Influenza Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Influenza Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Multivalent Influenza Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Multivalent Influenza Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Multivalent Influenza Vaccines Industry Trends Table 2. Multivalent Influenza Vaccines Industry Drivers Table 3. Multivalent Influenza Vaccines Industry Opportunities and Challenges Table 4. Multivalent Influenza Vaccines Industry Restraints Table 5. Global Multivalent Influenza Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Multivalent Influenza Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Multivalent Influenza Vaccines Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers Table 9. Global Multivalent Influenza Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Multivalent Influenza Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Multivalent Influenza Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Multivalent Influenza Vaccines Manufacturers, Product Type & Application Table 13. Global Multivalent Influenza Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Multivalent Influenza Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Quadrivalent Inactivated Influenza Vaccine (IIV4) Table 17. Major Manufacturers of Trivalent Inactivated Influenza Vaccine (IIV3) Table 18. Major Manufacturers of Trivalent Live Attenuated Vaccine (LAIV3) Table 19. Global Multivalent Influenza Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 21. Global Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 22. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2026) Table 23. Global Multivalent Influenza Vaccines Sales Market Share by Type (2027-2032) Table 24. Global Multivalent Influenza Vaccines Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (K Units) Table 26. Global Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (K Units) Table 27. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2026) Table 28. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of 6 Months to 3 Years Table 30. Major Manufacturers of Above 3 Years Table 31. Global Multivalent Influenza Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 33. Global Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 34. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2026) Table 35. Global Multivalent Influenza Vaccines Sales Market Share by Application (2027-2032) Table 36. Global Multivalent Influenza Vaccines Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (K Units) Table 38. Global Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (K Units) Table 39. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2026) Table 40. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2027-2032) Table 41. Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (K Units) Table 43. Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Multivalent Influenza Vaccines Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Multivalent Influenza Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 48. North America Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 49. Europe Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 51. Europe Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 58. Global Multivalent Influenza Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Multivalent Influenza Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Multivalent Influenza Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2026) Table 62. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2027-2032) Table 63. CSL Company Information Table 64. CSL Business Overview Table 65. CSL Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. CSL Multivalent Influenza Vaccines Product Portfolio Table 67. CSL Recent Development Table 68. KM Biologics Company Information Table 69. KM Biologics Business Overview Table 70. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. KM Biologics Multivalent Influenza Vaccines Product Portfolio Table 72. KM Biologics Recent Development Table 73. Viatris Company Information Table 74. Viatris Business Overview Table 75. Viatris Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Viatris Multivalent Influenza Vaccines Product Portfolio Table 77. Viatris Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. AstraZeneca Multivalent Influenza Vaccines Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Bcht Biotechnology Company Information Table 84. Bcht Biotechnology Business Overview Table 85. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio Table 87. Bcht Biotechnology Recent Development Table 88. Sinovac Company Information Table 89. Sinovac Business Overview Table 90. Sinovac Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Sinovac Multivalent Influenza Vaccines Product Portfolio Table 92. Sinovac Recent Development Table 93. Aleph Biomedical Company Information Table 94. Aleph Biomedical Business Overview Table 95. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio Table 97. Aleph Biomedical Recent Development Table 98. GSK Company Information Table 99. GSK Business Overview Table 100. GSK Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. GSK Multivalent Influenza Vaccines Product Portfolio Table 102. GSK Recent Development Table 103. ADIMMUNE Corporation Company Information Table 104. ADIMMUNE Corporation Business Overview Table 105. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio Table 107. ADIMMUNE Corporation Recent Development Table 108. Hualan Bio Company Information Table 109. Hualan Bio Business Overview Table 110. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Hualan Bio Multivalent Influenza Vaccines Product Portfolio Table 112. Hualan Bio Recent Development Table 113. Jiangsu GDK Company Information Table 114. Jiangsu GDK Business Overview Table 115. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio Table 117. Jiangsu GDK Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Sanofi Multivalent Influenza Vaccines Product Portfolio Table 122. Sanofi Recent Development Table 123. Shanghai Institute of Biological Products Company Information Table 124. Shanghai Institute of Biological Products Business Overview Table 125. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 127. Shanghai Institute of Biological Products Recent Development Table 128. Wuhan Institute of Biological Products Company Information Table 129. Wuhan Institute of Biological Products Business Overview Table 130. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 132. Wuhan Institute of Biological Products Recent Development Table 133. Changchun Institute of Biological Company Information Table 134. Changchun Institute of Biological Business Overview Table 135. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio Table 137. Changchun Institute of Biological Recent Development Table 138. Zhongyianke Biotech Company Information Table 139. Zhongyianke Biotech Business Overview Table 140. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio Table 142. Zhongyianke Biotech Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Multivalent Influenza Vaccines Distributors List Table 146. Multivalent Influenza Vaccines Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Multivalent Influenza Vaccines Product Image Figure 2. Global Multivalent Influenza Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Influenza Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Multivalent Influenza Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Multivalent Influenza Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Multivalent Influenza Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Quadrivalent Inactivated Influenza Vaccine (IIV4) Image Figure 9. Trivalent Inactivated Influenza Vaccine (IIV3) Image Figure 10. Trivalent Live Attenuated Vaccine (LAIV3) Image Figure 11. Global Multivalent Influenza Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Multivalent Influenza Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032) Figure 14. Global Multivalent Influenza Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Multivalent Influenza Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032) Figure 17. 6 Months to 3 Years Image Figure 18. Above 3 Years Image Figure 19. Global Multivalent Influenza Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Multivalent Influenza Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032) Figure 22. Global Multivalent Influenza Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Multivalent Influenza Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032) Figure 25. North America Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 27. U.S. Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 32. Germany Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 39. China Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Multivalent Influenza Vaccines Sales Market Share by Country (2021-2032) Figure 47. Brazil Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Multivalent Influenza Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Multivalent Influenza Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Multivalent Influenza Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Figure 58. North America Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Figure 60. Europe Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Multivalent Influenza Vaccines Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Multivalent Influenza Vaccines Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Quadrivalent Inactivated Influenza Vaccine (IIV4)
  • Trivalent Inactivated Influenza Vaccine (IIV3)
  • Trivalent Live Attenuated Vaccine (LAIV3)
Applications
  • 6 Months to 3 Years
  • Above 3 Years
Companies covered
  • CSL
  • KM Biologics
  • Viatris
  • AstraZeneca
  • Bcht Biotechnology
  • Sinovac
  • Aleph Biomedical
  • GSK
  • ADIMMUNE Corporation
  • Hualan Bio
  • Jiangsu GDK
  • Sanofi
  • Shanghai Institute of Biological Products
  • Wuhan Institute of Biological Products
  • Changchun Institute of Biological
  • Zhongyianke Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multivalent Influenza Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multivalent Influenza Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Multivalent Influenza Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Multivalent Influenza Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Multivalent Influenza Vaccines Market Dynamics
  1. 2.1 Multivalent Influenza Vaccines Industry Trends
  2. 2.2 Multivalent Influenza Vaccines Industry Drivers
  3. 2.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Influenza Vaccines Industry Restraints
3 Multivalent Influenza Vaccines Market by Manufacturers
  1. 3.1 Global Multivalent Influenza Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Multivalent Influenza Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Multivalent Influenza Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Multivalent Influenza Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multivalent Influenza Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Multivalent Influenza Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Multivalent Influenza Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multivalent Influenza Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multivalent Influenza Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multivalent Influenza Vaccines Tier 1, Tier 2, and Tier 3
4 Multivalent Influenza Vaccines Market by Type
  1. 4.1 Multivalent Influenza Vaccines Type Introduction
  2. 4.1.1 Quadrivalent Inactivated Influenza Vaccine (IIV4)
  3. 4.1.2 Trivalent Inactivated Influenza Vaccine (IIV3)
  4. 4.1.3 Trivalent Live Attenuated Vaccine (LAIV3)
  5. 4.2 Global Multivalent Influenza Vaccines Sales by Type
  6. 4.2.1 Global Multivalent Influenza Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Multivalent Influenza Vaccines Sales by Type (2021-2032)
  8. 4.2.3 Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032)
  9. 4.3 Global Multivalent Influenza Vaccines Revenue by Type
  10. 4.3.1 Global Multivalent Influenza Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  12. 4.3.3 Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032)
5 Multivalent Influenza Vaccines Market by Application
  1. 5.1 Multivalent Influenza Vaccines Application Introduction
  2. 5.1.1 6 Months to 3 Years
  3. 5.1.2 Above 3 Years
  4. 5.2 Global Multivalent Influenza Vaccines Sales by Application
  5. 5.2.1 Global Multivalent Influenza Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multivalent Influenza Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Multivalent Influenza Vaccines Revenue by Application
  9. 5.3.1 Global Multivalent Influenza Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032)
6 Global Multivalent Influenza Vaccines Sales by Region
  1. 6.1 Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multivalent Influenza Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Multivalent Influenza Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Multivalent Influenza Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Multivalent Influenza Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Multivalent Influenza Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Multivalent Influenza Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Multivalent Influenza Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Multivalent Influenza Vaccines Revenue by Region
  1. 7.1 Global Multivalent Influenza Vaccines Revenue by Region
  2. 7.1.1 Global Multivalent Influenza Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Multivalent Influenza Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Multivalent Influenza Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Multivalent Influenza Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Multivalent Influenza Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Multivalent Influenza Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Multivalent Influenza Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Multivalent Influenza Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 KM Biologics
  8. 8.2.1 KM Biologics Company Information
  9. 8.2.2 KM Biologics Business Overview
  10. 8.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
  12. 8.2.5 KM Biologics Recent Developments
  13. 8.3 Viatris
  14. 8.3.1 Viatris Company Information
  15. 8.3.2 Viatris Business Overview
  16. 8.3.3 Viatris Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
  18. 8.3.5 Viatris Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Bcht Biotechnology
  26. 8.5.1 Bcht Biotechnology Company Information
  27. 8.5.2 Bcht Biotechnology Business Overview
  28. 8.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
  30. 8.5.5 Bcht Biotechnology Recent Developments
  31. 8.6 Sinovac
  32. 8.6.1 Sinovac Company Information
  33. 8.6.2 Sinovac Business Overview
  34. 8.6.3 Sinovac Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
  36. 8.6.5 Sinovac Recent Developments
  37. 8.7 Aleph Biomedical
  38. 8.7.1 Aleph Biomedical Company Information
  39. 8.7.2 Aleph Biomedical Business Overview
  40. 8.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
  42. 8.7.5 Aleph Biomedical Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 ADIMMUNE Corporation
  50. 8.9.1 ADIMMUNE Corporation Company Information
  51. 8.9.2 ADIMMUNE Corporation Business Overview
  52. 8.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
  54. 8.9.5 ADIMMUNE Corporation Recent Developments
  55. 8.10 Hualan Bio
  56. 8.10.1 Hualan Bio Company Information
  57. 8.10.2 Hualan Bio Business Overview
  58. 8.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
  60. 8.10.5 Hualan Bio Recent Developments
  61. 8.11 Jiangsu GDK
  62. 8.11.1 Jiangsu GDK Company Information
  63. 8.11.2 Jiangsu GDK Business Overview
  64. 8.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
  66. 8.11.5 Jiangsu GDK Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Shanghai Institute of Biological Products
  74. 8.13.1 Shanghai Institute of Biological Products Company Information
  75. 8.13.2 Shanghai Institute of Biological Products Business Overview
  76. 8.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  78. 8.13.5 Shanghai Institute of Biological Products Recent Developments
  79. 8.14 Wuhan Institute of Biological Products
  80. 8.14.1 Wuhan Institute of Biological Products Company Information
  81. 8.14.2 Wuhan Institute of Biological Products Business Overview
  82. 8.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  84. 8.14.5 Wuhan Institute of Biological Products Recent Developments
  85. 8.15 Changchun Institute of Biological
  86. 8.15.1 Changchun Institute of Biological Company Information
  87. 8.15.2 Changchun Institute of Biological Business Overview
  88. 8.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
  90. 8.15.5 Changchun Institute of Biological Recent Developments
  91. 8.16 Zhongyianke Biotech
  92. 8.16.1 Zhongyianke Biotech Company Information
  93. 8.16.2 Zhongyianke Biotech Business Overview
  94. 8.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
  96. 8.16.5 Zhongyianke Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multivalent Influenza Vaccines Value Chain Analysis
  2. 9.1.1 Multivalent Influenza Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multivalent Influenza Vaccines Production Mode & Process
  6. 9.2 Multivalent Influenza Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multivalent Influenza Vaccines Distributors
  9. 9.2.3 Multivalent Influenza Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst